Pericyte Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
pericytes are mural cells embedded within the basement membrane of brain capillaries, where they maintain intimate contact with endothelial cells through peg-and-socket junctions, gap junctions, and shared basement membrane. Brain pericytes are approximately 100-fold more abundant in the central nervous system (CNS) microvasculature compared to peripheral tissues, reflecting their critical importance for blood-brain-barrier integrity, cerebral blood flow regulation, angiogenesis, immune surveillance, and waste clearance in the brain [@sweeney2019][@armulik2010]. [@armulik2010]
Pericyte Dysfunction In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
pericytes are mural cells embedded within the basement membrane of brain capillaries, where they maintain intimate contact with endothelial cells through peg-and-socket junctions, gap junctions, and shared basement membrane. Brain pericytes are approximately 100-fold more abundant in the central nervous system (CNS) microvasculature compared to peripheral tissues, reflecting their critical importance for blood-brain-barrier integrity, cerebral blood flow regulation, angiogenesis, immune surveillance, and waste clearance in the brain [@sweeney2019][@armulik2010]. [@armulik2010]
Pericyte dysfunction and loss have emerged as an early and mechanistically important event in alzheimers [@nation2019]
and other neurodegenerative conditions, potentially preceding classical pathological hallmarks such as [@van2020]
amyloid-beta deposition and tau/entities/tau-protein hyperphosphorylation. Cerebrospinal fluid ([CSF levels of soluble [@bell2011]
platelet-derived growth factor receptor beta (sPDGFRβ)—a biomarker of pericyte injury—begin rising from age 20, earlier than any established [@winkler2015]
AD biomarker, suggesting that vascular pericyte damage represents one of the earliest detectable changes in the aging brain [@nation2019][@van2020]. This [@zlokovic2011]
positions pericyte dysfunction as a critical bridge between the vascular hypothesis and the amyloid/tau cascades of neurodegeneration. [@hall2014]
Brain pericytes express a characteristic set of molecular markers including PDGFRβ (platelet-derived growth factor receptor beta), [@montagne2015]
NG2 (neural/glial antigen 2, also known as CSPG4), CD13 (aminopeptidase N), desmin, α-smooth muscle actin (α-SMA) (in [@blair2015]
arteriolar pericytes), and RGS5 (regulator of G 5). Single-cell RNA sequencing studies have revealed pericyte heterogeneity, with [@sagare2013]
distinct transcriptomic profiles along the arteriovenous axis of the microvasculature. Capillary pericytes (mid-capillary position) differ
from pre-capillary arteriolar and post-capillary venular pericytes in their contractile, immune, and barrier-related gene expression
programs [@sweeney2019][@armulik2010][@bell2011].
The PDGF-BB/PDGFRβ signaling axis is the master regulator of pericyte recruitment, survival, and function. Endothelial cells secrete
platelet-derived growth factor subunit B (PDGF-BB), which binds PDGFRβ on pericytes, activating PI3K/Akt, Ras/MAPK, and PLCγ signaling
cascades that promote pericyte proliferation, migration, survival, and vessel stabilization. Deficient PDGF-BB/PDGFRβ signaling—from reduced
endothelial PDGF-BB secretion, pericyte PDGFRβ downregulation, or disruption of the PDGF-BB retention motif—leads to progressive pericyte
loss, blood-brain-barrier breakdown, and neurodegeneration [@sweeney2019][@armulik2010][@winkler2015].
Genetically engineered mice with reduced PDGF-BB/PDGFRβ signaling (Pdgfbret/ret and Pdgfrβ+/- mice) develop age-dependent pericyte loss,
blood-brain-barrier breakdown, cerebral blood flow reduction, white matter disease, and cognitive
impairment that recapitulates features of human cerebral small vessel disease and early Alzheimer's pathology [@armulik2010][@winkler2015].
pericytes are essential for BBB formation during development and BBB maintenance throughout life. They induce and maintain tight junction
protein expression in endothelial cells (claudin-5, occludin, ZO-1), regulate transcytosis rates, and suppress expression of leukocyte
adhesion molecules. Pericyte-deficient mice exhibit BBB permeability to immunoglobulins, fibrinogen, and other plasma proteins, leading to
perivascular fibrin deposition, microglial activation, and neuronal injury. The BBB regulatory function of pericytes is mediated through
multiple mechanisms including TGF-β signaling, angiopoietin-1/Tie2 signaling, and Notch pathway activation [@sweeney2019][@armulik2010][@zlokovic2011].
pericytes regulate capillary diameter and regional cerebral blood flow (CBF) through contractile activity mediated by α-SMA and associated
contractile machinery. During functional hyperemia (neurovascular coupling), neuronal activity signals—including prostaglandins, nitric
oxide, and adenosine—cause pericyte relaxation and capillary dilation, increasing local blood flow to match metabolic demand. Pericyte
dysfunction impairs this neurovascular coupling, reducing oxygen and glucose delivery to active brain regions and contributing to the
cerebral-glucose-hypometabolism characteristic of neurodegeneration [@sweeney2019][@armulik2010][@bell2011].
Importantly, pericytes that constrict during ischemia may fail to relax during reperfusion ("no-reflow" phenomenon), contributing to ongoing microvascular dysfunction even after blood flow restoration. Pericyte rigor mortis following ischemic death has been demonstrated to cause persistent capillary constriction [@bell2011].
pericytes contribute to glymphatic-system function by regulating perivascular fluid flow and aqp4 (AQP4) polarization on
astrocytic endfeet. Pericyte loss disrupts the perivascular drainage pathway, impairing clearance of amyloid-beta and tau] [@sweeney2019][@hall2014].
When pericytes are injured or activated, the extracellular domain of PDGFRβ is cleaved by metalloproteinases (ADAM10, ADAM17) and shed into
the extracellular space, where it can be measured in CSF as soluble PDGFRβ (sPDGFRβ). Elevated CSF sPDGFRβ is a validated biomarker of
brain pericyte injury and BBB dysfunction, now investigated in large biomarker cohorts for Alzheimer's Disease and related dementias [@nation2019][@van2020][@montagne2015].
Longitudinal studies have revealed that CSF sPDGFRβ begins to increase continuously from approximately age 20, making it one of the
earliest detectable biomarker changes in the aging brain. This increase precedes elevations in phosphorylated tau]-181 (p-tau181, rising
from age ~22), total tau] (t-tau-protein, from age ~32), and the decline in CSF Aβ42 (from age ~40). This temporal sequence suggests that pericyte
injury and BBB dysfunction are among the earliest pathological events in the trajectory toward Alzheimer's Disease [@nation2019].
CSF sPDGFRβ levels are significantly elevated in alzheimers and mci compared to cognitively unimpaired
controls. sPDGFRβ correlates positively with CSF albumin quotient (a marker of BBB permeability), p-tau181, t-tau, and neurofilament light
chain (neurofilament-light, but the association with tau occurs independently of amyloid status, suggesting that pericyte damage interacts with tau
pathology through non-amyloid-dependent mechanisms [@van2020][@montagne2015][@blair2015].
A 2025 study dissecting BBB dysfunction biomarkers across neurodegenerative disorders found that CSF PDGFRβ levels were increased at the MCI stage and displayed significant positive associations with markers of neuroinflammation and synaptic markers, but were not directly associated with amyloid pathology [@blair2015]. This supports the view that pericyte dysfunction represents an independent pathological axis that amplifies neurodegeneration through vascular mechanisms.
Even in cognitively normal individuals, elevated CSF sPDGFRβ associates with higher amyloid PET uptake and greater longitudinal cognitive
decline, suggesting that pericyte injury is a preclinical risk factor for dementia. Individuals with elevated sPDGFRβ who are
amyloid-positive show accelerated tau accumulation compared to those with normal sPDGFRβ, consistent with the hypothesis that pericyte
dysfunction amplifies the downstream effects of amyloid pathology [@van2020][@montagne2015].
amyloid-beta peptides, particularly Aβ1-40, are directly toxic to pericytes. amyloid-beta accumulates in the walls of cerebral blood vessels in
cerebral-amyloid-angiopathy, where it triggers pericyte apoptosis through oxidative stress, mitochondrial dysfunction, and caspase
activation. Aβ1-40 is the predominant species in vascular amyloid deposits (compared to Aβ1-42 in parenchymal plaques) and specifically
targets the cerebrovasculature, reducing pericyte coverage and amplifying BBB breakdown [@armulik2010][@winkler2015][@sagare2013].
The apoe4/proteins/apoe, is associated with accelerated pericyte loss and BBB breakdown. ApoE4 pathway in pericytes, leading to tight
junction degradation and BBB permeability. APOE4 carriers show elevated CSF sPDGFRβ and CSF albumin quotient even before amyloid positivity,
suggesting that APOE4-driven pericyte dysfunction is an early, amyloid-independent mechanism of BBB damage [@armulik2010][@winkler2015].
In the alzheimers brain, pericyte constriction of capillaries reduces cerebral blood flow by 40–50% independently of amyloid
angiopathy. Neutrophil-pericyte interactions at capillary junctions ("capillary stalling") further reduce microvascular perfusion. Anti-Ly6G
antibodies that reduce neutrophil adhesion improve cerebral blood flow and cognitive function in AD mouse models, highlighting the interplay
between pericyte dysfunction, immune cell trafficking, and vascular insufficiency [@bell2011].
Pericytes are highly susceptible to oxidative-stress due to their high mitochondrial content and exposure to circulating pro-oxidant
molecules. Age-related accumulation of reactive oxygen species (oxidative-stress damages pericyte mitochondria, impairs contractile function, and
activates apoptotic cascades. Pericyte mitochondrial dysfunction may contribute to the "no-reflow" phenomenon, where damaged pericytes fail
to relax after ischemic episodes [@armulik2010][@bell2011].
Type 2 diabetes, a known risk factor for alzheimers and vascular-dementia, causes pericyte loss through advanced glycation end products (AGE)-rage signaling, hyperglycemia-induced oxidative stress, and PKC activation. Diabetic pericyte loss in retinal and cerebral microvasculature shares pathogenic mechanisms, connecting insulin resistance to neurovascular degeneration [@armulik2010].
Postmortem studies demonstrate 30–60% reduction in pericyte coverage of brain capillaries in alzheimers, with the greatest loss
in the hippocampus and prefrontal [cortex/brain-regions/[prefrontal-cortex. Pericyte degeneration correlates with BBB breakdown (as measured by fibrinogen extravasation
and IgG perivascular deposits), cerebral-amyloid-angiopathy severity, and amyloid-beta deposition. In AD mouse models, genetic pericyte depletion
(Pdgfrβ+/-; app/PS1 crosses) dramatically accelerates amyloid-beta pathology, tau phosphorylation, and neuronal loss, establishing a causal
relationship between pericyte dysfunction and AD pathology [@armulik2010][@winkler2015][@sagare2013].
BBB dysfunction and pericyte injury have been reported in parkinsons, particularly in the substantia-nigra and striatum. alpha-synuclein aggregates may damage pericytes through direct toxicity and activation of inflammatory cascades. Neuromelanin released from degenerating dopaminergic-neurons-snpc can activate pericytes and promote vascular inflammation [@armulik2010].
In als, BBB and blood-spinal cord barrier (BSCB) breakdown with pericyte loss has been demonstrated in both human postmortem tissue and SOD1 mutant mouse models. BSCB disruption occurs before motor neuron degeneration and symptom onset, suggesting that pericyte dysfunction may be an initiating event in ALS pathogenesis. CSF sPDGFRβ levels are elevated in ALS patients [@armulik2010].
cerebral-small-vessel-disease (SVD), a leading cause of vascular-dementia and a contributor to mixed dementia, is characterized by
arteriolosclerosis, lacunar infarcts, white matter hyperintensities, and microbleeds. Pericyte loss and dysfunction are central to SVD
pathogenesis, with reduced PDGF-BB/PDGFRβ signaling, collagen IV deposition, and basement membrane thickening. Genetic forms of SVD
(cadasil, carasil involve mutations affecting the neurovascular-unit, including pericyte function [@armulik2010][@zlokovic2011].
Restoring PDGF-BB/PDGFRβ signaling to promote pericyte survival and recruitment is a primary therapeutic strategy. Recombinant PDGF-BB
delivery (via AAV vectors or protein engineering with extended half-life) improves pericyte coverage and BBB integrity in animal models.
Small molecule PDGFRβ agonists are under development [@armulik2010][@winkler2015].
For APOE4-driven pericyte dysfunction, inhibiting the cyclophilin A (CypA)-nf-kb pathway represents a targeted approach. Cyclosporine A (CsA) inhibits CypA and restores BBB integrity in APOE4 mouse models. More selective CypA inhibitors with better CNS penetrance are being developed [@winkler2015].
Pericyte-like cells derived from induced pluripotent stem cells (iPSCs) or mesenchymal stem cells can be transplanted to restore pericyte coverage in damaged microvascular beds. Preclinical studies show that pericyte transplantation improves BBB integrity, reduces neuroinflammation, and improves cognitive function in aged and AD model mice [@armulik2010].
Strategies to improve cerebral blood flow regulation include phosphodiesterase inhibitors (cilostazol, which also reduces pericyte loss),
endothelin receptor antagonists, and NO donors targeted to the cerebrovasculature. Exercise, which enhances PDGF-BB production and pericyte
function, is a non-pharmacological intervention supported by epidemiological and mechanistic evidence [@armulik2010][@bell2011].
The study of Pericyte Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🟡 Moderate Confidence
| Dimension | Score |
|-----------|-------|
| Supporting Studies | 11 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 45%
Recent advances in this mechanism are being compiled. Check back for updates on key publications from 2024-2026.